Kozak & Associates’s CRISPR Therapeutics CRSP Stock Holding History

Kozak & Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.45K	Hold	26	–	–	﹤0.01%	367
2026 Q1	$1.43K	Hold	26	–	–	﹤0.01%	379
2025 Q4	$1.4K	Hold	26	–	–	﹤0.01%	381
2025 Q3	$1.44K	Hold	26	–	–	﹤0.01%	397
2025 Q2	$1.56K	Hold	26	–	–	﹤0.01%	360
2025 Q1	$1.01K	Hold	26	–	–	﹤0.01%	387
2024 Q4	$1.07K	Hold	26	–	–	﹤0.01%	380
2024 Q3	$1.27K	Hold	26	–	–	﹤0.01%	346
2024 Q2	$1.4K	Hold	26	–	–	﹤0.01%	334
2024 Q1	$1.45K	Hold	26	–	–	﹤0.01%	343
2023 Q4	$1.65K	Hold	26	–	–	﹤0.01%	325
2023 Q3	$1.12K	Hold	26	–	–	﹤0.01%	359
2023 Q2	$1.46K	Hold	26	–	–	﹤0.01%	318
2023 Q1	$1.18K	Hold	26	–	–	﹤0.01%	319
2022 Q4	$1K	Hold	26	–	–	﹤0.01%	318
2022 Q3	$2K	Hold	26	–	–	﹤0.01%	292
2022 Q2	$2K	Hold	26	–	–	﹤0.01%	330
2022 Q1	$2K	Hold	26	–	–	﹤0.01%	346
2021 Q4	$2K	Hold	26	–	–	﹤0.01%	346
2021 Q3	$2K	Buy	+26	New	+$3.27K	﹤0.01%	302

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kozak & Associates's CRSP Position: Q2 2026 in Review

Kozak & Associates held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 26 shares worth $1.45K. The position accounts for ﹤0.01% of the portfolio, ranked #367.

Kozak & Associates first reported a position in CRSP in Q3 2021 and has held it in 20 quarters since. The position peaked at $2K in Q3 2022. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Kozak & Associates held 26 shares of CRISPR Therapeutics worth $1.45K as of Q2 2026.
Kozak & Associates left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Kozak & Associates's portfolio in Q2 2026, its #367 holding.
Kozak & Associates first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 20 quarters since.
Kozak & Associates's CRISPR Therapeutics position peaked at $2K in Q3 2022.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Kozak & Associates's 13F filing for Q2 2026, filed 2 Jul 2026.